Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Eargo $165.2 million IPO
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 9…
Royalty Pharma $728 million secondary offering
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17…
Turmeric Acquisition $97.75 million IPO
Davis Polk advised the joint book-running managers in connection with the $97.75 million initial public offering of 9…
Acadia Healthcare $475 million high-yield notes offering
Davis Polk advised the representative of the initial purchasers of a Rule 144A/Regulation S offering by Acadia…
Smith+Nephew $1 billion notes offering
Davis Polk advised Smith & Nephew plc in connection with the establishment of a WKSI shelf and its debut SEC-registered…
Aziyo Biologics $50 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $50 million initial public…
NanoString Technologies $216.2 million follow-on offering
Davis Polk advised the joint book-running managers in connection with a $216.2 million public offering of 5,750,000…
Owens & Minor $200 million follow-on offering
Davis Polk advised the joint book-running managers and representatives to the underwriters in connection…
Beam Therapeutics $127 million offering
Davis Polk advised the joint book-running managers in connection with an SEC-registered offering of 5,750,000 common…
Biondvax Pharmaceuticals $100 million at-the-market offering
Davis Polk advised BiondVax Pharmaceuticals Ltd. in connection with its registered at-the-market offering of shares of its…